Management of dementia

Record ID 32018002267
Authors' objectives: Alzheimer disease (AD) is the most common cause of dementia. An estimated 190,000 people in Canada are living with mild Alzheimer-type dementia, while a further 532,000 to 799,000 people are affected by amnestic mild cognitive impairment ― an early stage of AD. The accumulation of amyloid plaques and neurofibrillary tangles in the brain are considered pathological hallmarks of the disease. A new drug that targets and aims to clear amyloid plaques from the brain was approved in the US in June 2021 and other similar drugs could soon be introduced. CADTH will be conducting a range of work to support decision-making about the management of dementia.
Project Status: Ongoing
Anticipated Publish Date: 2022
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Canada
MeSH Terms
  • Dementia
  • Alzheimer Disease
  • Drug Therapy
  • Patient Care
  • Dementia
  • Alzheimer's disease
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
Contact Email:

Canadian Agency for Drugs and Technologies in Health (CADTH)

This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.